59 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
26954324	77	Rapid, Structure-Based Exploration of Pipecolic Acid Amides as Novel Selective Antagonists of the FK506-Binding Protein 51.	Max Planck Institute of Psychiatry
26200936	39	Applications of Fluorine in Medicinal Chemistry.	Bristol-Myers Squibb Research and Development
26419422	33	Structure-Affinity Relationship Analysis of Selective FKBP51 Ligands.	Max Planck Institute of Psychiatry
26321603	8	Synthesis and anticancer effects evaluation of 1-alkyl-3-(6-(2-methoxy-3-sulfonylaminopyridin-5-yl)benzo[d]thiazol-2-yl)urea as anticancer agents with low toxicity.	Xi'An Jiaotong University
26102506	40	Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115.	Celgene
26083478	66	Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223.	Celgene
23647266	35	Increasing the efficiency of ligands for FK506-binding protein 51 by conformational control.	Max Institute of Psychiatry
8627611	17	Structure-based design of novel, urea-containing FKBP12 inhibitors.	Agouron Pharmaceuticals
	6	High-affinity FKBP-12 ligands derived from (R)-()-carvone. Synthesis and evaluation of FK506 pyranose ring replacements	TBA
	12	Design, synthesis and evaluation of dual domain FKBP ligands	TBA
21413808	170	Synopsis of some recent tactical application of bioisosteres in drug design.	Bristol-Myers Squibb Pharmaceutical Research and Development
22455444	93	Evaluation of synthetic FK506 analogues as ligands for the FK506-binding proteins 51 and 52.	Max Planck Institute of Psychiatry
22455398	122	Exploration of pipecolate sulfonamides as binders of the FK506-binding proteins 51 and 52.	Max Planck Institute of Psychiatry
21142106	28	Pipecolic acid derivatives as small-molecule inhibitors of the Legionella MIP protein.	University of Wu£Rzburg
16134928	34	Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry.	The Scripps Research Institute
7241506	40	New analgesic drugs derived from phencyclidine.	TBA
9857082	67	Immunophilins: beyond immunosuppression.	Guilford Pharmaceuticals
10091702	2	Cleavage of the cyclohexyl-subunit of rapamycin results in loss of immunosuppressive activity.	Novartis Pharma
	13	Synthesis of FK506-Cyclosporin hybrid macrocycles	TBA
	8	Design, synthesis and X-ray crystallographic studies of [7.3.1] and [8.3.1] macrocyclic FKBP-12 ligands	TBA
	8	Preparation and in vitro activities of naphthyl and indolyl ether derivatives of the FK-506 related immunosuppressive macrolide ascomycin	TBA
	1	Synthesis and FKBP binding of small molecule mimics of the tricarbonyl region of FK506	TBA
	15	Alkyl ether derivatives of the FK-506 related, immunosuppressive macrolide L-683,742 (C31-O-desmethyl ascomycin)	TBA
	4	Alkyl ether analogs of the FK-506 related, immunosuppressive macrolide L-683,590 (ascomycin)	TBA
	7	Synthesis and evaluation of dual domain macrocyclic FKBP12 ligands.	TBA
	2	Synthesis and study of a non macrocyclic FK506 derivative.	TBA
	4	The contribution to binding of the pyranoside substituents in the excised binding domain of FK-506	TBA
	2	The affinity of the excised binding domain of FK-506 for the immunophilin FKBP12.	TBA
18038971	88	Nuclear magnetic resonance fragment-based identification of novel FKBP12 inhibitors.	University of California San Diego
12951089	13	Regulation of gene expression by synthetic dimerizers with novel specificity.	Ariad Gene Therapeutics
12139466	11	Synthesis of N-glyoxyl prolyl and pipecolyl amides and thioesters and evaluation of their in vitro and in vivo nerve regenerative effects.	Guilford Pharmaceuticals
11992791	53	Solid-phase synthesis of FKBP12 inhibitors: N-sulfonyl and N-carbamoylprolyl/pipecolyl amides.	Guilford Pharmaceuticals
11992790	40	Use of parallel-synthesis combinatorial libraries for rapid identification of potent FKBP12 inhibitors.	Guilford Pharmaceuticals
10888319	5	Antifungal rapamycin analogues with reduced immunosuppressive activity.	Abbott Laboratories
10741553	8	Fluoresceinated FKBP12 ligands for a high-throughput fluorescence polarization assay.	Bristol-Myers Squibb Pharmaceutical Research Institute
10737745	20	Investigating protein-ligand interactions with a mutant FKBP possessing a designed specificity pocket.	Ariad Gene Therapeutics
10543889	4	Retention of immunosuppressant activity in an ascomycin analogue lacking a hydrogen-bonding interaction with FKBP12.	Abbott Laboratories
10479292	16	Synthesis and cytotoxic evaluation of cycloheximide derivatives as potential inhibitors of FKBP12 with neuroregenerative properties.	Max-Planck Research Unit
10450987	22	Potent immunosuppressive C32-O-arylethyl ether derivatives of ascomycin with reduced toxicity.	Merck Research Laboratories
10450986	7	C32-O-phenalkyl ether derivatives of the immunosuppressant ascomycin: a tether length study.	Merck Research Laboratories
31693351	473	Discovery of 4	TBA
29400967	136	Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.	Bristol-Myers Squibb
9873523	5	C32-O-imidazol-2-yl-methyl ether derivatives of the immunosuppressant ascomycin with improved therapeutic potential.	Merck Research Laboratories
30565923	34	Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.	Eberhard Karls University T£Bingen
9767630	9	Investigations of neurotrophic inhibitors of FK506 binding protein via Monte Carlo simulations.	Yale University
9599228	27	32-Ascomycinyloxyacetic acid derived immunosuppressants. Independence of immunophilin binding and immunosuppressive potency.	Abbott Laboratories
16854055	13	Simplified cyclic analogues of bastadin-5. Structure-activity relationships for modulation of the RyR1/FKBP12 Ca2+ channel complex.	University of California
29578710	26	Chemogenomic Profiling of Human and Microbial FK506-Binding Proteins.	Max Planck Institute of Psychiatry
29308895	24	Highly Selective, Potent, and Oral mTOR Inhibitor for Treatment of Cancer as Autophagy Inducer.	Nankai University
28412204	27	A calcineurin antifungal strategy with analogs of FK506.	Amplyx Pharmaceuticals
14993260	2	FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): A peripheral efficacious kappa opioid agonist with unprecedented selectivity.	University of Arizona